|
26 May 2023 |
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
|
|
25 May 2023 |
Topas Therapeutics Initiates Phase 2a Clinical Trial for TPM502 in Celiac Disease; Appoints Chief Business Officer and Chief Operating Officer
|
|
24 May 2023 |
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
|
|
13 May 2023 |
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
|
|
10 May 2023 |
Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV
|
|
10 May 2023 |
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
|
|
10 May 2023 |
Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
|
|
05 May 2023 |
Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist
|
|
04 May 2023 |
US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
|
|
28 Apr 2023 |
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine
|
|
28 Apr 2023 |
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
|
|
27 Apr 2023 |
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors
|
|
19 Apr 2023 |
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
|
|
18 Apr 2023 |
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
|
|
18 Apr 2023 |
Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting
|
|
18 Apr 2023 |
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
|
|
17 Apr 2023 |
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
|
|
17 Apr 2023 |
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
|
|
17 Apr 2023 |
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Com
|
|
12 Apr 2023 |
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
|
|
04 Apr 2023 |
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
|
|
31 Mar 2023 |
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
|
|
30 Mar 2023 |
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
|
|
27 Mar 2023 |
Allergy Therapeutics announces dosing of patients has commenced in Phase I PROTECT trial investigating novel peanut allergy vaccine candidate, VLP Peanut
|
|
21 Mar 2023 |
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
|
